Retraction notice to "Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis." Kidney Int Rep . 2021;6:613-623.

Autor: Provenzano R; School of Medicine, Wayne State University, Detroit, Michigan, USA., Fishbane S; Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA., Szczech L; FibroGen, Inc., San Francisco, California, USA., Leong R; FibroGen, Inc., San Francisco, California, USA., Saikali KG; FibroGen, Inc., San Francisco, California, USA., Zhong M; FibroGen, Inc., San Francisco, California, USA., Lee TT; FibroGen, Inc., San Francisco, California, USA., Houser MT; AstraZeneca, Gaithersburg, Maryland, USA., Frison L; AstraZeneca, Mölndal, Sweden., Houghton J; AstraZeneca, Gaithersburg, Maryland, USA., Little DJ; AstraZeneca, Gaithersburg, Maryland, USA., Peony Yu KH; FibroGen, Inc., San Francisco, California, USA., Neff TB; FibroGen, Inc., San Francisco, California, USA.

Publikováno v: Kidney international reports [Kidney Int Rep] 2022 Feb 05; Vol. 7 (3), pp. 665. Date of Electronic Publication: 2022 Feb 05 (Print Publication: 2022).

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.

Autor: Provenzano R; Department of Internal Medicine, Wayne State University, Detroit, Michigan provenzanorobert5@gmail.com., Szczech L; FibroGen, Inc., San Francisco, California., Leong R; FibroGen, Inc., San Francisco, California., Saikali KG; FibroGen, Inc., San Francisco, California., Zhong M; FibroGen, Inc., San Francisco, California., Lee TT; FibroGen, Inc., San Francisco, California., Little DJ; AstraZeneca, Gaithersburg, Maryland., Houser MT; AstraZeneca, Gaithersburg, Maryland., Frison L; AstraZeneca, Mölndal, Sweden., Houghton J; AstraZeneca, Gaithersburg, Maryland., Neff TB; FibroGen, Inc., San Francisco, California.; Deceased.

Publikováno v: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2021 Aug; Vol. 16 (8), pp. 1190-1200.

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.

Autor: Provenzano R; Department of Medicine, Wayne State University, Detroit, Michigan, USA., Tumlin J; Southeast Renal Research Institute, Chattanooga, Tennessee, USA., Zabaneh R; Northwest Louisiana Nephrology Research, Shreveport, Louisiana, USA., Chou J; FibroGen, Inc., San Francisco, California, USA., Hemmerich S; FibroGen, Inc., San Francisco, California, USA., Neff TB; FibroGen, Inc., San Francisco, California, USA., Yu KP; FibroGen, Inc., San Francisco, California, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2020 Nov; Vol. 60 (11), pp. 1432-1440. Date of Electronic Publication: 2020 Jun 30.

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Autor: Chen N; Institute of Nephrology, Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Qian J; Renji Hospital, Shanghai, China., Chen J; Zhejiang University, Hangzhou, China., Yu X; Sun Yat-Sen University, Guangzhou, China., Mei C; Changzheng Hospital, Shanghai, China., Hao C; Shanghai Huashan Hospital, Shanghai, China., Jiang G; Xinhua Hospital, Jiaotong University, Shanghai, China., Lin H; Dalian Medical University, Dalian, China., Zhang X; Shenzhen People's Hospital, Shenzhen, China., Zuo L; Beijing University First Hospital, Beijing, China., He Q; Sichuan Province Hospital, Chengdu, China., Fu P; West China Hospital, Chengdu, China., Li X; Union Medical College Hospital, Beijing, China., Ni D; FibroGen, Inc., San Francisco, CA, USA., Hemmerich S; FibroGen, Inc., San Francisco, CA, USA., Liu C; FibroGen, Inc., San Francisco, CA, USA., Szczech L; FibroGen, Inc., San Francisco, CA, USA., Besarab A; FibroGen, Inc., San Francisco, CA, USA., Neff TB; FibroGen, Inc., San Francisco, CA, USA., Peony Yu KH; FibroGen, Inc., San Francisco, CA, USA., Valone FH; FibroGen, Inc., San Francisco, CA, USA.

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2017 Aug 01; Vol. 32 (8), pp. 1373-1386.

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Autor: Provenzano R; St. John Hospital & Medical Center, Detroit, MI., Besarab A; FibroGen, Inc, San Francisco, CA., Wright S; US Renal Care, Pine Bluff, AR., Dua S; Valley Renal Medical Group, Northridge, CA., Zeig S; Pines Clinical Research, Pembroke Pines, FL., Nguyen P; US Renal Care, Ft Worth, TX., Poole L; FibroGen, Inc, San Francisco, CA., Saikali KG; FibroGen, Inc, San Francisco, CA., Saha G; FibroGen, Inc, San Francisco, CA., Hemmerich S; FibroGen, Inc, San Francisco, CA., Szczech L; FibroGen, Inc, San Francisco, CA., Yu KH; FibroGen, Inc, San Francisco, CA. Electronic address: pyu@fibrogen.com., Neff TB; FibroGen, Inc, San Francisco, CA.

Publikováno v: American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2016 Jun; Vol. 67 (6), pp. 912-24. Date of Electronic Publication: 2016 Feb 02.